Compare LAW & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | MYGN |
|---|---|---|
| Founded | 2013 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.2M | 481.6M |
| IPO Year | 2021 | 1996 |
| Metric | LAW | MYGN |
|---|---|---|
| Price | $4.44 | $4.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $8.00 | $7.64 |
| AVG Volume (30 Days) | 597.5K | ★ 1.5M |
| Earning Date | 05-25-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $156,849,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $11.23 | $7.19 |
| Revenue Next Year | $10.60 | $5.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.29 | 2.33 |
| 52 Week Low | $2.45 | $3.76 |
| 52 Week High | $9.11 | $10.32 |
| Indicator | LAW | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 45.81 |
| Support Level | $3.92 | $3.93 |
| Resistance Level | $4.81 | $5.63 |
| Average True Range (ATR) | 0.40 | 0.41 |
| MACD | 0.23 | 0.07 |
| Stochastic Oscillator | 78.72 | 48.76 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.